| Cat. No. |
Product Name |
Information |
| PC-22656 |
HRS-4642
KRAS G12D inhibitor
|
HRS-4642 is a high affinity, selective, long-acting, and non-covalent KRAS G12D inhibitor with SPR KD of 0.083 nM, >20-fold selective over wild-type KRAS and KRAS G12C. |
| PC-22626 |
Glecirasib
KRAS G12C inhibitor
|
Glecirasib (JAB-21822) is a highly selective, covalent oral KRAS G12C inhibitor, demonstrated promising clinical activity in NSCLC and CRC. |
| PC-21542 |
CSC01
KRAS G13D inhibitor
|
CSC01 (CSC057253844) is a small molecule inhibitor of oncogenic KRAS mutant G13D (KRAS-G13D). |
| PC-21063 |
RMC-4998
KRAS G12C inhibitor
|
RMC-4998 (RM-029) is a tricomplex inhibitor that targets the active state or GTP-bound state of KRAS G12C, selectively inhibits the proliferation of KRASG12C mutant cells with mean IC50 of 0.28 nM. |
| PC-20878 |
BI-2493
pan-KRAS inhibitor
|
BI-2493 is a structural analogue of BI-2865 for in vivo administration, BI-2493 a potent, inactive state selective, non-covalent pan KRAS inhibitor. |
| PC-20877 |
BI-2865
pan-KRAS inhibitor
|
BI-2865 is a potent, inactive state selective, non-covalent pan KRAS inhibitor, binds to the GDP-loaded state of WT, G12C, G12D, G12V and G13D KRAS with high affinity (ITC Kd values,10-40 nM), inactivates common cancer-causing KRAS mutants. |
| PC-20608 |
RMC-6291
KRAS G12C inhibitor
|
RMC-6291 (RMC6291) is a potent, covalent, next-generation, mutant-selective inhibitor of active state KRAS G12C(ON) with IC50 of 0.7 nM (pERK), RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). |
| PC-20249 |
SCH53239
Ras inhibitor
|
SCH-53239 (SCH53239) is a small molecule inhibitor of Ras nucleotide exchange with IC50 of 0.5 uM, bind competitively with GDP in the nucleotide binding site of the Ras protein. |
| PC-20037 |
Fulzerasib
KRAS G12C inhibitor
|
Fulzerasib (IBI351, IBI-351) is a potent covalent and irreversible inhibitor of KRAS G12C. |
| PC-49554 |
RSC-1255
V-ATPase inhibitor
|
RSC-1255 (KRAS inhibitor 249C, V-ATPase inhibitor) is a Ras-mutant selective cytotoxic agent with nanomolar potency against a spectrum of Ras-mutant cancer cells (A549 (KRASG12S), IC50=73 nM), binds to V-ATPase (Kd=23 nM) and inhibits its activity. |
| PC-49406 |
BI-0474
KRAS G12C inhibitor
|
BI-0474 (BI 0474) is a potent, in vivo active KRAS G12C inhibitor with IC50 of 7.0 nM in GDP-KRAS::SOS1 protein-protein interaction assay. |
| PC-38706 |
BC-DXI-32982
DX2-KRAS inhibitor
|
BC-DXI-32982 is a specific small molecule DX2-KRAS inhibitor that specifically binds to the KRAS-binding region of AIMP2-DX2, inhibits interaction between DX2 and KRAS4B with IC50 of 0.18 uM. |
